MAIA Biotechnology
MAIA
6 hedge funds and large institutions have $1.04M invested in MAIA Biotechnology in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
37% more capital invested
Capital invested by funds: $763K → $1.04M (+$280K)
0.6% more ownership
Funds ownership: 2.11% → 2.71% (+0.6%)
33% less funds holding
Funds holding: 9 → 6 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$174K |
| 2 |
CWM
Centric Wealth Management
Chicago,
Illinois
|
+$139K |
| 3 |
BlackRock
New York
|
+$1.04K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$39K |
| 2 |
Jane Street
New York
|
-$34K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.39K |
| 4 |
OIA
Optimum Investment Advisors
Chicago,
Illinois
|
-$3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
1
Lynwood Capital Management
Toronto,
Ontario, Canada
| $878K | +$174K | +50,215 | +25% |
|
|
CWM
2
Centric Wealth Management
Chicago,
Illinois
| $141K | +$139K | +40,206 | New |
|
|
3
BlackRock
New York
| $13.6K | +$1.04K | +302 | +8% |
|
|
4
UBS Group
Zurich,
Switzerland
| $10.6K | -$5.39K | -1,558 | -34% |
|
5
Wells Fargo
San Francisco,
California
| $49 | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $7 | +$7 | +2 | New |
|
|
7
Millennium Management
New York
| – | -$39K | -11,811 | Closed |
|
|
8
Jane Street
New York
| – | -$34K | -10,210 | Closed |
|
|
OIA
9
Optimum Investment Advisors
Chicago,
Illinois
| – | -$3K | -1,000 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$1K | -311 | Closed |
|
MAIA Hedge Fund Activity: Q4 2022 in Review
6 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q4 2022, worth a combined $1.04M — up 37% from $763K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MAIA and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Lynwood Capital Management, adding an estimated $174K. The largest seller was Millennium Management, exiting entirely with an estimated $39K sold.
- 6 institutional investors held MAIA Biotechnology (MAIA) as of Q4 2022, down from 9 in Q3 2022.
- Funds reported $1.04M of MAIA Biotechnology stock for Q4 2022, up 37% quarter-over-quarter.
- 2 funds opened new MAIA Biotechnology positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest MAIA Biotechnology buyer in Q4 2022 was Lynwood Capital Management, an estimated $174K added.
- The largest MAIA Biotechnology seller in Q4 2022 was Millennium Management, an estimated $39K sold.
Based on aggregated 13F filings for Q4 2022.